Takeda Pharmaceutical Company Limited
CYCLOPROPANAMINE COMPOUND AND USE THEREOF

Last updated:

Abstract:

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula ##STR00001## wherein each symbol is as defined in the present specification, or a salt thereof.

Status:
Application
Type:

Utility

Filling date:

16 Feb 2021

Issue date:

17 Jun 2021